Boris Pasche: Karmanos Cancer Institute Leads Innovation in Cancer and Hematologic Disease Treatment
Boris Pasche, President and CEO at Karmanos Cancer Institute, shared a post on LinkedIn:
“Karmanos Cancer Institute continues to lead in medical science by providing patients with exceptional treatment opportunities for cancer and hematologic diseases.
As a pioneer in Theranostics, phase I trials, medical devices, and now gene therapy for hemophilia, Karmanos exemplifies its mission to transform care, research, and education in these fields through courage, commitment, and compassion.
With 17 locations throughout Michigan, Karmanos also offers second opinions, often introducing patients to novel therapies they may not have previously considered.
For more information on their groundbreaking work, check out this article: Karmanos is first independent cancer center to treat hemophilia B with new gene therapy.”
Stay updated with Hemostasis Today.
-
Mar 25, 2026, 15:52Indunil Karunarathna: Kawasaki Disease at the Intersection of Immunology, Cardiology, and Vascular Biology
-
Mar 25, 2026, 15:48Micah Grey: Reflecting on an Incredible Experience at the THSNA Congress
-
Mar 25, 2026, 15:45Christi Miller: Exploring Key Facts about Hemophilia During Bleeding Disorders Awareness Month
-
Mar 25, 2026, 15:44Stéphane Laurent: Why the Relationship Between AfSBT and ISBT Matters in Blood Management
-
Mar 25, 2026, 15:36Seema Dawood: EDTA-Induced Platelet Satellitism
-
Mar 25, 2026, 15:35ABO-Incompatible Transfusions and Severe Allergic Reactions – ISBT
-
Mar 25, 2026, 15:14Critical Gaps in AF Stroke Prevention – JTH
-
Mar 25, 2026, 15:09Paul Empey: Excited to Invite You to Enjoy and Tune Into a Great NBDF Event
-
Mar 25, 2026, 15:05Allison Burnett: Antithrombosis Stewardship Is No Longer a Future Concept